IPP Bureau
Indica Labs receives FDA clearance for HALO AP Dx digital pathology platform
By IPP Bureau - May 23, 2024
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
AstraZeneca plans $1.5 billion ADCs manufacturing facility in Singapore
By IPP Bureau - May 22, 2024
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
AstraZeneca sets ambition to deliver US$ 80 billion revenue by 2030
By IPP Bureau - May 22, 2024
Launch of 20 new medicines expected by 2030
Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
By IPP Bureau - May 22, 2024
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
Biocon Biologics’ receives FDA approval for Biosimilar Aflibercept for Yesafili
By IPP Bureau - May 21, 2024
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
.jpeg "ASG opens its branch of super-specialty eye hospitals in Noida")
ASG opens its branch of super-specialty eye hospitals in Noida
By IPP Bureau - May 21, 2024
ASG Group of Eye Hospitals has 165+ branches in 85+ cities across India and abroad
Dupixent late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
By IPP Bureau - May 21, 2024
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
Modular ATP study of the mCRM System meets primary safety and efficacy endpoints
By IPP Bureau - May 21, 2024
Additional data from APPRAISE ATP trial reinforce modular therapy approach
IIHMR Start-ups inks MoU with BMCHRC & HCG Hospital
By IPP Bureau - May 20, 2024
The collaboration aims to bolster healthcare entrepreneurship
LVPEI raises awareness and funds for retinoblastoma treatment with WHITATHON Run
By IPP Bureau - May 20, 2024
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
Supernova Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19
By IPP Bureau - May 20, 2024
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi approved by USFDA
By IPP Bureau - May 20, 2024
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
MMV and GSK win Society of Chemical Industry Innovation Award
By IPP Bureau - May 20, 2024
The award recognizes powerful science–industry collaborations for social good
Glenmark receives ANDA approval for Brimonidine Tartrate and Timolol Maleate ophthalmic solution
By IPP Bureau - May 18, 2024
According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million
